280 completed, 39 terminated, 12 withdrawn, 10 active not recruiting. 161 Phase 1, 141 Phase 2, 30 Phase 3, 17 Phase 4, 4 Not applicable.
Follow MedImmune LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC Standard of Care - mFOLFOX6, E1 - mFOLFOX and durvalumab, E2 - mFOLFOX6, durvalumab and oleclumab - Microsatellite-stable Colorectal Cancer | Phase 2 | Withdrawn | MedImmune LLC | 2020-10-01 | 2020-09-21 | |
| PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma Durvalumab, Tremelimumab, TDS-IM v1.0 System - Renal Cell Carcinoma | Phase 2 | Withdrawn | Washington University School of Medicine | 2020-08-31 | 2020-08-13 | |
| A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma MEDI5752, Axitinib, Lenvatinib - Advanced Renal Cell Carcinoma | Phase 1 | Active not recruiting | MedImmune LLC | 67 | 2020-08-05 | 2025-07-25 |
| Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza Oseltamivir, MEDI8852, Placebo - Influenza | Phase 2 | Withdrawn | MedImmune LLC | 2020-04-03 | 2020-01-18 | |
| IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. IPH5201, durvalumab, oleclumab - Advanced Solid Tumors | Phase 1 | Completed | MedImmune LLC | 57 | 2020-03-03 | 2022-08-15 |
| Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus Placebo, Cotadutide - Type 2 Diabetes | Phase 1 | Completed | AstraZeneca | 16 | 2020-01-21 | 2020-07-31 |
| A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors MEDI5395, Durvalumab - Advanced Solid Tumors | Phase 1 | Completed | MedImmune LLC | 39 | 2019-10-24 | 2023-02-21 |
| A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide cotadutide multidose pen injection - Type 2 Diabetes Mellitus | Phase 1 | Completed | MedImmune LLC | 36 | 2019-09-27 | 2020-04-07 |
| A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. MEDI0382 high dose, Placebo for MEDI0382 high dose, MEDI0382 low dose - Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | MedImmune LLC | 74 | 2019-09-23 | 2023-01-17 |
| COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC Durvalumab, Oleclumab, FOLFOX - Metastatic Microsatellite-stable Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | MedImmune LLC | 61 | 2019-09-13 | 2026-08-11 |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy Durvalumab, Neoantigen DNA vaccine, TDS-IM system (Inchor Medical Systems) - Triple Negative Breast Cancer, Triple Negative Breast Neoplasms | Phase 1 | Terminated | Washington University School of Medicine | 18 | 2019-07-23 | 2024-05-28 |
| A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors MEDI1191, Durvalumab - Solid Tumors, Cancer | Phase 1 | Completed | MedImmune LLC | 61 | 2019-05-08 | 2024-10-02 |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Resectable, Early-stage | Phase 2 | Completed | MedImmune LLC | 84 | 2019-03-08 | 2022-02-24 |
| Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection Diabetic Foot Ulcer | Withdrawn | University of Texas Southwestern Medical Center | 2019-02-01 | 2019-02-26 | ||
| Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism MEDI6012, Placebo - Cardiovascular Diseases | Phase 2 | Terminated | Columbia University | 7 | 2019-01-31 | 2024-11-12 |
| A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus MEDI0382, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | MedImmune LLC | 20 | 2019-01-07 | 2020-06-05 |
| A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors MEDI7247 - Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 | Completed | MedImmune LLC | 8 | 2018-12-20 | 2019-12-30 |
| Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab - Stage III Non-small Cell Lung Cancer, Unresectable | Phase 2 | Completed | MedImmune LLC | 189 | 2018-12-19 | 2024-10-08 |
| GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors feladilimab, Tremelimumab, Docetaxel - Neoplasms | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 26 | 2018-11-26 | 2024-08-28 |
| Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus MEDI6570, Placebo, Part B Placebo - Atherosclerosis, Cardiovascular Disease | Phase 1 | Completed | MedImmune LLC | 88 | 2018-09-28 | 2020-08-24 |
Showing 20 of 345. Sign in to see all of them.
Influenza, Human (43) · Neoplasms (26) · Asthma (25) · Diabetes Mellitus, Type 2 (14) · Carcinoma, Non-Small-Cell Lung (13) · Head and Neck Neoplasms (10) · Respiratory Syncytial Virus Infections (10) · Colorectal Neoplasms (9) · Lupus Erythematosus, Systemic (9) · Lymphoma, Non-Hodgkin (9) · Pulmonary Disease, Chronic Obstructive (9) · Arthritis, Rheumatoid (8) · Leukemia (8) · Lymphoma (8) · Melanoma (8)
durvalumab (55) · FluMist (29) · tremelimumab (28) · cotadutide (15) · motavizumab (12) · Amifostine (9) · immunotoxin HA22 (9) · inebilizumab (9) · siplizumab (9) · tralokinumab (9) · Influenza Vaccines (8) · sifalimumab (8) · Bevacizumab (7) · enokizumab (7) · etaracizumab (7)
United States (268) · Canada (57) · United Kingdom (50) · France (38) · Spain (38) · Germany (36) · Poland (36) · Australia (28) · Hungary (25) · Czechia (23) · Italy (22) · Belgium (21) · Israel (20) · South Korea (20) · Japan (19)
Robert Walker, MD (20) · Barbara White, M.D. (5) · Raburn Mallory, MD (5) · Elissa Malkin, D.O. (4) · Edward Piper, MBBS (3) · J. Bruce McClain, M.D. (3) · Judith Falloon, MD (3) · Luz Hammershaimb, MD (3) · M. Pamela Griffin, M.D. (3) · Raburn Mallory, M.D. (3) · Robert Walker, M.D. (3)
PMID 33687069, PMID 19446146, PMID 21060780, PMID 21356110, PMID 21798883, PMID 26189934, PMID 28758192, PMID 30658649, PMID 31112385, PMID 31575508, PMID 31660791, PMID 32816849, PMID 36542692, PMID 15545863, PMID 16061911, PMID 17167135, PMID 17301299, PMID 18299305, PMID 18310199, PMID 18596230, PMID 19258920, PMID 19395948, PMID 19479852, PMID 19483659, PMID 19634161, PMID 19796721, PMID 20008423, PMID 20036102, PMID 20522609, PMID 20525274, PMID 20638452, PMID 20686436, PMID 21060320, PMID 21440036, PMID 21445003, PMID 21496468, PMID 21513761, PMID 21782874, PMID 21926667, PMID 22355053, PMID 23400715, PMID 23434567, PMID 23602668, PMID 23754736, PMID 24050312, PMID 24080653, PMID 24204744, PMID 24356256, PMID 24559157, PMID 24622396
2018 (4), 2014 (3), 2015 (3), 2017 (2), 2019 (2), 2023 (2), P30CA060553 (2), 2008 (1), 2009 (1), 2016 (1), P30CA006516 (1), P30CA015704 (1), R01CA136551 (1), R01CA240983 (1)